Sign In
Buy ACAD
$22.60
+0.510 (+2.31%)
At Close: Jun 23, 2026
Investing in Biotech ETFs
04:56pm, Friday, 20'th Jan 2023 The Motley Fool
Here are the five best biotech ETFs to invest in right now.
Acadia Pharmaceuticals: What's Ahead In 2023
02:04pm, Monday, 16'th Jan 2023
Today, we are circling back on mid-cap biopharma ACADIA Pharmaceuticals Inc. for the first time since the spring of 2021. The company had one major disappointment in 2022, but has some potential new d
Axsome (AXSM) Rides on New Drug Approval & Sunosi Buyout
02:35pm, Friday, 30'th Dec 2022 Zacks Investment Research
Axsome (AXSM) receives FDA approval for Auvelity to treat major depressive disorder in August. The Sunosi deal and promising pipeline bode well. Stiff competition in the target market remains a woe.
Mizuho Maintains Neutral Rating for ACADIA Pharmaceuticals: Here's What You Need To Know
05:05pm, Wednesday, 21'st Dec 2022 Benzinga
Mizuho has decided to maintain its Neutral rating of ACADIA Pharmaceuticals (NASDAQ:ACAD) and lower its price target from $17.00 to $15.00.
Shares of ACADIA Pharmaceuticals are trading up 0.71% over t
Acadia Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
04:05pm, Wednesday, 21'st Dec 2022
SAN DIEGO--( BUSINESS WIRE )--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 9:00
Acadia (ACAD) Up 3.5% Since Last Earnings Report: Can It Continue?
04:31pm, Friday, 02'nd Dec 2022 Zacks Investment Research
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Acadia (ACAD) Up 3.5% Since Last Earnings Report: Can It Continue?
12:48pm, Friday, 02'nd Dec 2022
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
Acadia Pharmaceuticals: I Remain Cautiously Bullish After Q3 Updates
05:16pm, Friday, 04'th Nov 2022
Acadia released its Q322 earnings this week. Revenues of $131m and a net loss of $27.2m are about par for the course. Acadia's only approved drug Nuplazid is approved to treat Parkinson's Disease Psyc
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022
02:41pm, Friday, 04'th Nov 2022 Benzinga
Upgrades
Citigroup upgraded the previous rating for Advanced Energy Industries Inc (NASDAQ:AEIS) from Neutral to Buy. For the third quarter, Advanced Energy Indus had an EPS of $2.12, compared to yea
Acadia's (ACAD) Q3 Loss Narrower Than Expected, Revenues Miss
04:23pm, Thursday, 03'rd Nov 2022 Zacks Investment Research
Acadia (ACAD) reports a narrower-than-expected loss in the third quarter of 2022 while revenues fall shy of estimates. Tightens guidance for Nuplazid.
ACADIA Pharmaceuticals, Inc. (ACAD) Q3 2022 Earnings Call Transcript
10:13pm, Wednesday, 02'nd Nov 2022
ACADIA Pharmaceuticals, Inc. (NASDAQ:ACAD ) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Mark Johnson - VP, IR Stephen Davis - CEO & Director Brendan Teehan - EVP,
Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Misses Revenue Estimates
09:35pm, Wednesday, 02'nd Nov 2022 Zacks Investment Research
Acadia (ACAD) delivered earnings and revenue surprises of 5.56% and 6.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Misses Revenue Estimates
06:52pm, Wednesday, 02'nd Nov 2022
Acadia (ACAD) delivered earnings and revenue surprises of 5.56% and 6.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Viatris (VTRS) to Report Q3 Earnings: What's in the Cards?
05:13pm, Tuesday, 01'st Nov 2022 Zacks Investment Research
Viatris (VTRS) Q3 results are likely to be impacted by foreign exchange rate fluctuations. An update on the deal with Biocon is also expected along with the results.
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
02:27pm, Tuesday, 01'st Nov 2022 Benzinga
Upgrades
For AnaptysBio Inc (NASDAQ:ANAB), Guggenheim upgraded the previous rating of Neutral to Buy. AnaptysBio earned $1.15 in the second quarter, compared to $0.02 in the year-ago quarter. The sto
